- Rheumatoid Arthritis Slideshow Pictures
- Take the RA Quiz
- Joint-Friendly Exercises to Reduce RA Pain Slideshow
Does Cimzia (certolizumab) cause side effects?
Cimzia (certolizumab) is an injectable synthetic protein antibody that binds to tumor necrosis factor alpha (TNFα) in the body and blocks the effects of TNFα in patients with rheumatoid arthritis and Crohn's disease.
Inflammation is the body's reaction to injury and is a necessary process for the repair of injury. TNF is a protein that the body produces when there is inflammation. TNF promotes inflammation and the signs of inflammation, which, in the case of arthritis, include fever as well as pain, tenderness, and swelling of joints.
In the case of Crohn's disease, the signs of inflammation include fever, abdominal pain, and diarrhea. The unchecked inflammation of rheumatoid arthritis eventually leads to destruction of the joints. The inflammation in Crohn's disease can lead to strictures (narrowing) of the intestine or intestinal perforation.
Cimzia binds to TNF in the body and thereby blocks the effects of TNF. As a result, inflammation and its consequences in the joints and intestine are reduced. In arthritis, the progressive destruction of the joints is slowed or prevented.
Common side effects of Cimzia include
- respiratory tract infections,
- urinary tract infections (UTIs),
- joint pain,
- abdominal pain,
- intestinal obstruction, and
- injection site reactions (redness, pain and itching).
Serious side effects of Cimzia include
- serious infections (such as tuberculosis, sepsis, and fungal infections),
- worsening or new diseases of the nervous system,
- worsening congestive heart failure,
- possible cancer,
- hypersensitivity (allergic) reactions (including anaphylaxis),
- reduced levels in the blood of platelets and red blood cells (aplastic anemia), and
- increased risk of reactivating hepatitis B virus in chronic carriers of the virus.
Drug interactions of Cimzia include anakinra, abatacept, rituximab, or natalizumab because the combination may result in reduced white blood cells in the blood (neutropenia), serious infections and no additional benefit.
- Cimzia may interfere with the effectiveness of vaccines.
- Live vaccines, including attenuated vaccines, should not be used while patients are being treated with Cimzia.
- Cimzia may interfere with tests of coagulation in patients receiving blood thinners.
What are the important side effects of Cimzia (certolizumab)?
The most common adverse effects in clinical studies were:
- respiratory tract infections,
- urinary tract infections, and
- arthralgia (pain in the joints),
- abdominal pain,
- intestinal obstruction,
- pain and
- itching at the site of injection.
Like other drugs that block TNFα, use of certolizumab has been associated with serious infections such as tuberculosis, sepsis (bacteria in the blood) and fungal infections. Individuals with active infections should not be treated with certolizumab. Certolizumab may worsen or cause new diseases of the nervous system.
Certolizumab also may cause or worsen congestive heart failure. In studies, some patients who used certolizumab or other TNFα blocking drugs developed cancer. Since patients with Crohn's disease have a higher risk of cancers than the general population, the connection between cancer and use of certolizumab is unclear.
Other side effects of certolizumab include hypersensitivity (allergic) reactions (including anaphylaxis) and reduced levels in the blood of platelets and red blood cells (aplastic anemia). Certolizumab may increase the risk of reactivating hepatitis B virus in chronic carriers of the virus.
Cimzia (certolizumab) side effects list for healthcare professionals
The most serious adverse reactions were:
- Serious Infections
- Heart Failure
Clinical Trials Experience
Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug, and may not predict the rates observed in a broader patient population in clinical practice.
In premarketing controlled trials of all patient populations combined the most common adverse reactions (≥ 8%) were
Adverse Reactions Most Commonly Leading To Discontinuation Of Treatment In Premarketing Controlled Trials
The proportion of patients with Crohn’s disease who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for Cimzia and 7% for placebo. The most common adverse reactions leading to the discontinuation of Cimzia (for at least 2 patients and with a higher incidence than placebo) were
- abdominal pain (0.4% Cimzia, 0.2% placebo),
- diarrhea (0.4% Cimzia, 0% placebo), and
- intestinal obstruction (0.4% Cimzia, 0% placebo).
The proportion of patients with rheumatoid arthritis who discontinued treatment due to adverse reactions in the controlled clinical studies was 5% for Cimzia and 2.5% for placebo. The most common adverse reactions leading to discontinuation of Cimzia were
Controlled Studies With Crohn’s Disease
- The data described below reflect exposure to Cimzia at 400 mg subcutaneous dosing in studies of patients with Crohn’s disease.
- In the safety population in controlled studies, a total of 620 patients with Crohn’s disease received Cimzia at a dose of 400 mg, and 614 subjects received placebo (including subjects randomized to placebo in Study CD2 following open label dosing of Cimzia at Weeks 0, 2, 4).
- In controlled and uncontrolled studies, 1,564 patients received Cimzia at some dose level, of whom 1,350 patients received 400 mg Cimzia.
- Approximately 55% of subjects were female, 45% were male, and 94% were Caucasian. The majority of patients in the active group were between the ages of 18 and 64.
- During controlled clinical studies, the proportion of patients with serious adverse reactions was 10% for Cimzia and 9% for placebo.
- The most common adverse reactions (occurring in ≥ 5% of Cimzia-treated patients, and with a higher incidence compared to placebo) in controlled clinical studies with Cimzia were upper respiratory infections (e.g. nasopharyngitis, laryngitis, viral infection) in 20% of Cimzia-treated patients and 13% of placebo-treated patients, urinary tract infections (e.g. bladder infection, bacteriuria, cystitis) in 7% of Cimzia-treated patients and in 6% of placebo-treated patients, and arthralgia (6% Cimzia, 4% placebo).
Other Adverse Reactions
The most commonly occurring adverse reactions in controlled trials of Crohn’s disease were described above. Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn’s disease and other diseases, occurring in patients receiving Cimzia at doses of 400 mg or other doses include:
- Blood and lymphatic system disorders: Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.
- Cardiac disorders: Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.
- Eye disorders: Optic neuritis, retinal hemorrhage, and uveitis.
- General disorders and administration site conditions: Bleeding and injection site reactions.
- Hepatobiliary disorders: Elevated liver enzymes and hepatitis.
- Immune system disorders: Alopecia totalis.
- Psychiatric disorders: Anxiety, bipolar disorder, and suicide attempt.
- Renal and urinary disorders: Nephrotic syndrome and renal failure.
- Reproductive system and breast disorders: Menstrual disorder.
- Skin and subcutaneous tissue disorders: Dermatitis, erythema nodosum, and urticaria.
- Vascular disorders: Thrombophlebitis, vasculitis.
Controlled Studies with Rheumatoid Arthritis
- Cimzia was studied primarily in placebo-controlled trials and in long-term follow-up studies.
- The data described below reflect the exposure to Cimzia in 2,367 RA patients, including 2,030 exposed for at least 6 months, 1,663 exposed for at least one year and 282 for at least 2 years; and 1,774 in adequate and well-controlled studies.
- In placebo-controlled studies, the population had a median age of 53 years at entry; approximately 80% were females, 93% were Caucasian and all patients were suffering from active rheumatoid arthritis, with a median disease duration of 6.2 years.
- Most patients received the recommended dose of Cimzia or higher.
- Table 1 summarizes the reactions reported at a rate of at least 3% in patients treated with Cimzia 200 mg every other week compared to placebo (saline formulation), given concomitantly with methotrexate.
Table 1: Adverse Reactions Reported by ≥3% of Patients Treated with
Cimzia Dosed Every Other Week during Placebo-Controlled Period of Rheumatoid Arthritis Studies, with Concomitant Methotrexate.
|Placebo+ MTX# (%)
|Cimzia 200 mg EOW + MTX(%)
|Upper respiratory tract||2||6|
|#EOW = Every other Week, MTX = Methotrexate.|
Hypertensive adverse reactions were observed more frequently in patients receiving Cimzia than in controls. These adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and non-steroidal anti-inflammatory drugs.
Patients receiving Cimzia 400 mg as monotherapy every 4 weeks in rheumatoid arthritis controlled clinical trials had similar adverse reactions to those patients receiving Cimzia 200 mg every other week.
Other Adverse Reactions
- Other infrequent adverse reactions (occurring in less than 3% of RA patients) were similar to those seen in Crohn’s disease patients.
Psoriatic Arthritis Clinical Study
- Cimzia has been studied in 409 patients with psoriatic arthritis (PsA) in a placebo-controlled trial.
- The safety profile for patients with PsA treated with Cimzia was similar to the safety profile seen in patients with RA and previous experience with Cimzia.
Ankylosing Spondylitis Clinical Study
- Cimzia has been studied in 325 patients with axial spondyloarthritis of whom the majority had ankylosing spondylitis (AS) in a placebo-controlled study (AS-1).
- The safety profile for patients in study AS-1 treated with Cimzia was similar to the safety profile seen in patients with RA.
Plaque Psoriasis Clinical Studies
- In clinical studies, a total of 1112 subjects with plaque psoriasis were treated with Cimzia.
- Of these, 779 subjects were exposed for at least 12 months, 551 for 18 months, and 66 for 24 months.
- Data from three placebo-controlled studies (Studies PS-1, PS-2, and PS-3) in 1020 subjects (mean age 46 years, 66% males, 94% white) were pooled to evaluate thesafety of Cimzia.
Placebo-Controlled Period (Week 0-16)
- In the placebo-controlled period of Studies PS-1, PS-2 and PS-3 in the 400 mg group, adverse events occurred in 63.5% of subjects in the Cimzia group compared to 61.8% of subjects in the placebo group.
- The rates of serious adverse events were 4.7% in the Cimzia group and 4.5% in the placebo group.
- Table 2 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the Cimzia group than in the placebo group.
Table 2: Adverse Reactions Occurring in ≥1% of Subjects in the
Cimzia Group and More
Frequently than in the Placebo Group in the Plaque Psoriasis Studies PS-1, PS-2, and PS-3.
|Adverse Reactions||Cimzia 400 mg every other week
|Cimzia 200 mg 5 every other week
|Upper respiratory tract infections1||75 (21.9)||68 (19.4)||33 (21.0)|
|Headache2||13 (3.8)||10 (2.9)||4 (2.5)|
|Injection site reactions3||11 (3.2)||6 (1.7)||1 (0.6)|
|Cough||11 (3.2)||4 (1.1)||3 (1.9)|
|Herpes infections4||5 (1.5)||5 (1.4)||2 (1.3)|
1: Upper respiratory tract infection cluster includes upper respiratory tract infection, pharyngitis bacterial, pharyngitis streptococcal, upper respiratory tract infection bacterial, viral upper respiratory tract infection, viral pharyngitis, viral sinusitis, and nasopharyngitis.
2: Headache includes headache and tension headache.
3: Injection site reactions cluster includes injection site reaction, injection site erythema, injection site bruising, injection site discoloration, injection site pain, and injection site swelling.
4: Herpes infections cluster includes oral herpes, herpes dermatitis, herpes zoster, and herpes simplex.
5: Subjects received 400 mg of Cimzia at Weeks 0, 2, and 4, followed by 200 mg every other week.
Elevated Liver Enzymes
- Elevated liver enzymes were reported more frequently in the Cimzia-treated subjects (4.3% in the 200 mg group and 2.3% in the 400 mg group) than in the placebo-treated subjects (2.5%).
- Of Cimzia-treated subjects who had elevation of liver enzymes, two subjects were discontinued from the trial.
- In controlled Phase 3 studies of Cimzia in adults with PsO with a controlled period duration ranging from 0 to 16 weeks, AST and/or ALT elevations ≥5 x ULN occurred in 0.9% of Cimzia 200 mg or Cimzia 400 mg arms and none in placebo arm.
Psoriasis-Related Adverse Events
- In controlled clinical studies in psoriasis, change of plaque psoriasis into a different psoriasis sub-types (including erythrodermic, pustular and guttate), was observed in <1% of Cimzia treated subjects.
Adverse Reactions Of Special Interest Across Indications
- The incidence of infections in controlled studies in Crohn’s disease was 38% for Cimzia-treated patients and 30% for placebo-treated patients.
- The infections consisted primarily of upper respiratory infections (20% for Cimzia, 13% for placebo).
- The incidence of serious infections during the controlled clinical studies was 3% per patient-year for Cimzia-treated patients and 1% for placebo-treated patients.
- Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.
- The incidence of new cases of infections in controlled clinical studies in rheumatoid arthritis was 0.91 per patient-year for all Cimzia-treated patients and 0.72 per patient-year for placebo-treated patients.
- The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.
- In the controlled rheumatoid arthritis studies, there were more new cases of serious infection adverse reactions in the Cimzia treatment groups, compared to the placebo groups (0.06 per patient-year for all Cimzia doses vs. 0.02 per patient-year for placebo).
- Rates of serious infections in the 200 mg every other week dose group were 0.06 per patient-year and in the 400 mg every 4 weeks dose group were 0.04 per patient-year.
- Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.
- In the placebo group, no serious infection occurred in more than one subject.
- There is no evidence of increased risk of infections with continued exposure over time.
- In controlled clinical studies in psoriasis, the incidence rates of infections were similar in the Cimzia and placebo groups.
- The infections consisted primarily of upper respiratory tract infections and viral infections (including herpes infections).
- Serious adverse events of infection occurred in Cimzia-treated patients during the placebo-controlled periods of the pivotal studies (pneumonia, abdominal abscess, and hematoma infection) and Phase 2 study (urinary tract infection, gastroenteritis, and disseminated tuberculosis).
Tuberculosis And Opportunistic Infections
- In completed and ongoing global clinical studies in all indications including 5,118 Cimzia-treated patients, the overall rate of tuberculosis is approximately 0.61 per 100 patient-years across all indications.
- The majority of cases occurred in countries with high endemic rates of TB.
- Reports include cases of disseminated (miliary, lymphatic, and peritoneal) as well as pulmonary TB.
- The median time to onset of TB for all patients exposed to Cimzia across all indications was 345 days. In the studies with Cimzia in RA, there were 36 cases of TB among 2,367 exposed patients, including some fatal cases.
- Rare cases of opportunistic infections have also been reported in these clinical trials. In Phase 2 and Phase 3 studies with Cimzia in plaque psoriasis, there were 2 cases of TB among 1112 exposed patients.
- In clinical studies of Cimzia, the overall incidence rate of malignancies was similar for Cimzia-treated and control patients.
- For some TNF blockers, more cases of malignancies have been observed among patients receiving those TNF blockers compared to control patients.
- In placebo-controlled and open-label studies, cases of new or worsening heart failure have been reported for Cimzia-treated patients.
- The majority of these cases were mild to moderate and occurred during the first year of exposure.
- The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following Cimzia administration to patients:
- In clinical studies in Crohn’s disease, 4% of patients treated with Cimzia and 2% of patients treated with placebo that had negative baseline ANA titers developed positive titers during the studies.
- One of the 1,564 Crohn’s disease patients treated with Cimzia developed symptoms of a lupus-like syndrome.
- In clinical trials of TNF blockers, including Cimzia, in patients with RA, some patients have developed ANA.
- Four patients out of 2,367 patients treated with Cimzia in RA clinical studies developed clinical signs suggestive of a lupus-like syndrome.
- The impact of long-term treatment with Cimzia on the development of autoimmune diseases is unknown.
- As with all therapeutic proteins, there is potential for immunogenicity.
- The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
- Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.
- For these reasons, comparison of the incidence of antibodies to certolizumab pegol in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.
- Patients with Crohn’s disease were tested at multiple time points for antibodies to certolizumab pegol during Studies CD1 and CD2.
- In patients continuously exposed to Cimzia, the overall percentage of patients who were antibody positive to Cimzia on at least one occasion was 8%; approximately 6% were neutralizing in vitro.
- No apparent correlation of antibody development to adverse events or efficacy was observed.
- Patients treated with concomitant immunosuppressants had a lower rate of antibody development than patients not taking immunosuppressants at baseline (3% and 11%, respectively).
- The following adverse events were reported in Crohn’s disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242):
- In two long-term (up to 7 years of exposure), open-label Crohn’s disease studies, overall 23% (207/903) of patients developed antibodies against certolizumab pegol on at least one occasion.
- Of the 207 patients who were antibody positive, 152 (73%) had a persistent reduction of drug plasma concentration, which represents 17% (152/903) of the study population.
- The data from these two studies do not suggest an association between the development of antibodies and adverse events.
- The overall percentage of patients with antibodies to certolizumab pegol detectable on at least one occasion was 7% (105 of 1,509) in the rheumatoid arthritis placebo-controlled trials.
- Approximately one third (3%, 39 of 1,509) of these patients had antibodies with neutralizing activity in vitro.
- Patients treated with concomitant immunosuppressants (MTX) had a lower rate of antibody development than patients not taking immunosuppressants at baseline.
- Patients treated with concomitant immunosuppressant therapy (MTX) in RA-I, RA-II, RA-III had a lower rate of neutralizing antibody formation overall than patients treated with Cimzia monotherapy in RA-IV (2% vs. 8%).
- Both the loading dose of 400 mg every other week at Weeks 0, 2 and 4 and concomitant use of MTX were associated with reduced immunogenicity.
- Antibody formation was associated with lowered drug plasma concentration and reduced efficacy.
- In patients receiving the recommended Cimzia dosage of 200 mg every other week with concomitant MTX, the ACR20 response was lower among antibody positive patients than among antibody-negative patients (Study RA-I, 48% versus 60%; Study RA-II 35% versus 59%, respectively).
- In Study RA-III, too few patients developed antibodies to allow for meaningful analysis of ACR20 response by antibody status.
- In Study RA-IV (monotherapy), the ACR20 response was 33% versus 56%, antibody-positive versus antibody-negative status, respectively.
- No association was seen between antibody development and the development of adverse events.
- Approximately 8 % (22/265) and 19% (54/281) of subjects with psoriasis who received Cimzia 400 mg every 2 weeks and Cimzia 200 mg every 2 weeks for 48 weeks, respectively, developed antibodies to certolizumab pegol.
- Of the subjects who developed antibodies to certolizumab pegol, 45% (27/60) had antibodies that were classified as neutralizing.
- Antibody formation was associated with lowered drug plasma concentration and reduced efficacy.
- The data reflect the percentage of patients whose test results were considered positive for antibodies to certolizumab pegol in an ELISA, and are highly dependent on the sensitivity and specificity of the assay.
The following adverse reactions have been identified during post-approval use of Cimzia. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.
- Vascular disorder: systemic vasculitis has been identified during post-approval use of TNF blockers.
- Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.
- Immune System Disorders: sarcoidosis
- Neoplasms benign, malignant and unspecified (including cysts and polyps): Melanoma, Merkel cell carcinoma (neuroendocrine carcinoma of the skin).
What drugs interact with Cimzia (certolizumab)?
Use With Anakinra, Abatacept, Rituximab, And Natalizumab
- An increased risk of serious infections has been seen in clinical studies of other TNF-blocking agents used in combination with anakinra or abatacept, with no added benefit.
- Formal drug interaction studies have not been performed with rituximab or natalizumab.
- Because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of Cimzia in these combinations.
- There is not enough information to assess the safety and efficacy of such combination therapy.
- Therefore, the use of Cimzia in combination with anakinra, abatacept, rituximab, or natalizumab is not recommended.
- Avoid use of live (including attenuated) vaccines concurrently with Cimzia.
- Interference with certain coagulation assays has been detected in patients treated with Cimzia.
- Certolizumab pegol may cause erroneously elevated activated partial thromboplastin time (aPTT) assay results in patients without coagulation abnormalities.This effect has been observed with the PTT-Lupus Anticoagulant (LA) test and Standard Target Activated Partial Thromboplastin time (STA-PTT) Automate tests from Diagnostica Stago, and the HemosIL APTT-SP liquid and HemosIL lyophilized silica tests from Instrumentation Laboratories.
- Other aPTT assays may be affected as well. Interference with thrombin time (TT) and prothrombin time (PT) assays has not been observed.
- There is no evidence that Cimzia therapy has an effect on in vivo coagulation.
Cimzia (certolizumab) is an injectable synthetic protein antibody that binds to tumor necrosis factor alpha (TNFa) in the body and blocks the effects of TNFa in patients with rheumatoid arthritis and Crohn's disease. Common side effects of Cimzia include respiratory tract infections, urinary tract infections (UTIs), joint pain, abdominal pain, diarrhea, intestinal obstruction, and injection site reactions (redness, pain and itching). There are no adequate studies of Cimzia in pregnant women. It is unknown if Cimzia is excreted in breast milk.
Multimedia: Slideshows, Images & Quizzes
What Is Rheumatoid Arthritis (RA)? Symptoms, Treatment, Diagnosis
What is rheumatoid arthritis (RA)? Learn about treatment, diagnosis, and the symptoms of juvenile rheumatoid arthritis. Discover...
Osteoarthritis (OA): Treatment, Symptoms, Diagnosis
Osteoarthritis (OA) is a degenerative joint disease most often affecting major joints such as knees, hands, back, or hips....
Rheumatoid Arthritis: Alternative RA Therapies
Learn which alternative treatments show promise for rheumatoid arthritis.
Exercises for Knee Osteoarthritis and Joint Pain
Learn about osteoarthritis and exercises that relieve knee osteoarthritis pain, stiffness and strengthen the knee joint and...
Rheumatoid Arthritis: RA Food Myths and Facts
Is there really an RA diet? Learn the truth from WebMD about which foods can ease your symptoms and which you should avoid.
Psoriatic Arthritis Symptoms, Treatment, Diagnosis
Psoriatic arthritis pain can be treated. Get more information on the causes, symptoms, diagnosis, and medications for psoriatic...
Rheumatoid Arthritis Exercises: Joint-Friendly Workouts
Regular exercise boosts fitness and helps reverse joint stiffness for people with rheumatoid arthritis (RA). WebMD demonstrates...
Rheumatoid Arthritis: RA Home Remedies That Don't Work
People try all sorts of things to relieve rheumatoid arthritis pain. WebMD debunks some of the common ones and lets you know what...
Tips for Healthy Joints: Exercise, Nutrition, & More
Dealing with joint pain and arthritis? Learn why weight matters--and why NOT to stretch before exercise. See these solutions for...
Arthritis: 16 Bad Habits That Cause Joint Pain
Being overweight, wearing uncomfortable shoes, or carrying a heavy purse can make joint pain and arthritis symptoms worse. Some...
Osteoarthritis Quiz: Test Your Medical IQ
How does osteoarthritis differ from other types of arthritis? Learn about osteoarthritis with this quiz.
Osteoarthritis: 15 Tips to Improve Daily Living With OA
Have arthritis in the knee? Osteoarthritis joint pain can make it hard to carry out activities of daily living. Cartilage...
Psoriatic Arthritis Quiz: Test Your Medical IQ
How is psoriatic arthritis related to psoriasis? Take this quiz to find out!
Rheumatoid Arthritis Quiz: What is Rheumatoid Arthritis?
How is rheumatoid arthritis different from other forms of arthritis, such as osteoarthritis and gout? Take the Rheumatoid...
Picture of Psoriatic Arthritis
Psoriatic arthritis is a specific condition in which a person has both psoriasis and arthritis. See a picture of Psoriatic...
Picture of Osteoarthritis
Osteoarthritis is a type of arthritis that is caused by the breakdown and eventual loss of the cartilage of one or more...
Famous Faces With Rheumatoid Arthritis
Learn more about the famous faces of rheumatoid arthritis such as Lucille Ball, Glenn Frey, and more.
Arthritis: Causes and Treatment for Joint Stiffness and Pain
Arthritis and injuries can leave your joints swollen, tender, and damaged. Discover treatments for morning stiffness, sore...
Fun With Kids? Don't Let Arthritis Stop You
You can still have lots of fun with children despite arthritis. Our experts uncover ways to spend time with your kids or...
Exercises for Osteoarthritis -- Yoga, Swimming, & More
Check out this slideshow on Active Living From Day to Night with Osteoarthritis. Even with arthritis you can keep your active...
Related Disease Conditions
16 Early Rheumatoid Arthritis (RA) Signs & Symptoms
Early rheumatoid arthritis (RA) symptoms and signs vary differently from person to person. The most common body parts that are initially affected by RA include the small joints of the hands, wrists, and feet, and the knees and hip joints. Joint inflammation causes stiffness. Warmth, redness, and pain may vary in degree.
Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints, the tissue around the joints, as well as other organs in the body. Early RA signs and symptoms include anemia, both sides of the body affected (symmetric), depression, fatigue, fever, joint deformity, joint pain, joint redness, joint stiffness, joint swelling, joint tenderness, joint warmth, limping, loss of joint function, loss of joint range of motion, and polyarthritis.
12 Early Signs of Arthritis in Hands
Hand arthritis occurs when there is inflammation in one or more joints of the hand and wrist. A few of the common types of arthritis that affect the hands are osteoarthritis, rheumatoid arthritis, post-traumatic arthritis (arthritis as a result of an injury), psoriatic arthritis and gout.
Which Foods Make Arthritis Worse?
Certain foods can contribute to arthritis joint inflammation, like processed foods high in salt, alcohol, red meat, and others. Foods that are good for the joints are beans, greens, and other whole foods that have high fiber and nutrient content and low calories.
Buildup of uric acid crystals in a joint causes gouty arthritis. Symptoms and signs include joint pain, swelling, heat, and redness, typically of a single joint. Gout may be treated with diet and lifestyle changes, as well as medication.
Arthritis (Joint Inflammation)
Arthritis is inflammation of one or more joints. When joints are inflamed they can develop stiffness, warmth, swelling, redness and pain. There are over 100 types of arthritis, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, lupus, gout, and pseudogout.
14 Early Signs of Arthritis in the Legs
Leg arthritis affects the joints of the hips, knees, ankles or feet. The early signs and symptoms of arthritis in the legs include pain, swelling, stiffness, decreased range of motion, trouble walking, fever, bump-like swelling, and other symptoms.
Osteoarthritis is a type of arthritis caused by inflammation, breakdown, and eventual loss of cartilage in the joints. Also known as degenerative arthritis, osteoarthritis can be caused by aging, heredity, and injury from trauma or disease.
Second Source article from Government
Pain Management and Rheumatoid Arthritis
Second Source article from WebMD
Second Source article from Government
Rheumatoid Arthritis vs. Fibromyalgia
Though rheumatoid arthritis (RA) and fibromyalgia have similar symptoms, RA is an autoimmune disease and fibromyalgia is a chronic pain syndrome. RA symptoms include joint redness, swelling, and pain that lasts more than 6 weeks. Fibromyalgia symptoms include widespread pain, tingling feet or hands, depression, and bowel irritability. Home remedies for both include stress reduction, exercise, and getting enough sleep.
Osteoarthritis vs. Osteoporosis Differences and Similarities
Arthritis is defined as painful inflammation and joint stiffness. Osteoarthritis is a type of arthritis and the most common cause of chronic joint pain, affecting over 25 million Americans. Osteoarthritis is a type of arthritis that involves the entire joint. Osteoporosis is not a type of arthritis. It is a disease that mainly is caused by a loss of bone tissue that is not limited to the joint areas. It is possible for one person to have both osteoarthritis and osteoporosis. The differences in the signs and symptoms of osteoarthritis and osteoporosis include; pain, stiffness, and joint swelling, joint deformity, crackle sounds when the joint is moving, and walking with a limp. Osteoporosis is called the "silent disease" because it can progress for years without signs and symptoms before it is diagnosed, severe back pain, bone fractures, height loss, and difficulty or inability to walk. The differences in the causes of osteoarthritis and osteoporosis are that osteoarthritis usually is caused by wear and tear on the joints. Osteoporosis usually is caused by one or more underlying problems, for example, calcium and vitamin D deficiencies. Treatment for osteoarthritis and osteoporosis are not the same. There is no cure for osteoarthritis or osteoporosis.
Early Signs and Symptoms of Arthritis in Knuckles
Pain, swelling, and tenderness are usually considered as early signs and symptoms of knuckle arthritis. Tiny bumps pop out on the top knuckles of some of the fingers, and fingers become stiff.
Septic arthritis, or infectious arthritis, is infection of one or more joints by bacteria, viruses, or fungi. Symptoms and signs of septic arthritis include fever, joint pain, chills, swelling, redness, warmth, and stiffness. Treatment involves antibiotics and the drainage of the infected joint.
Psoriatic arthritis is a disease that causes skin and joint inflammation. Symptoms and signs include painful, stiff, and swollen joints, tendinitis, and organ inflammation. Treatment involves anti-inflammatory medications and exercise.
17 Early Signs of Arthritis in the Back
Arthritis in the back arises due to the inflammation of facet joints in the spine or sacroiliac joints between the spine and the pelvis. Some of the early signs of arthritis in the back include back pain, stiffness, swelling, bone grinding, loss of flexibility, fatigue, muscle spasms and other symptoms.
Fungal arthritis is inflammation of a joint by a fungus that has invaded the body and is growing in the normally sterile joint. Fungal arthritis symptoms and signs include pain, redness, loss of range of motion, and swelling. Fungal arthritis treatment includes antibiotics, adequate drainage of the joint, and sometimes surgery.
Reactive arthritis is a chronic, systemic rheumatic disease characterized by three conditions, including conjunctivitis, joint inflammation, and genital, urinary, or gastrointestinal system inflammation. Inflammation leads to pain, swelling, warmth, redness, and stiffness of the affected joints. Non-joint areas may experience irritation and pain. Treatment for reactive arthritis depends on which area of the body is affected. Joint inflammation is treated with anti-inflammatory medications.
Can Rheumatoid Arthritis Be Caused by Stress?
Rheumatoid arthritis can be caused by and result in stress, as well as other conditions such as gastrointestinal problems (IBD).
11 Home Remedies for Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a long-term disorder that progressively affects many parts of the body. Home remedies, diet, and lifestyle changes can help reduce pain and discomfort associated with RA alongside medical treatment. Home remedies alone cannot effectively treat RA or prevent the progression of the disease.
What Are the Four Stages of Rheumatoid Arthritis?
Rheumatoid arthritis is a chronic inflammatory disease categorized into the following four stages and classifications. Learn the causes, symptoms, and complications of RA below.
Arthritis in Knee: 4 Stages of Osteoarthritis
Painful joint swelling is called arthritis. Osteoarthritis is due to wear and tear of the joints over many years. Arthritis maye develop in any joint, including the fingers, hips and knees. Usually, patients with arthritis feel pain in their joints even after moderate movements. There are four stages of osteoarthritis of the knee.
Rheumatoid Arthritis vs. Arthritis
Arthritis is a general term used to describe joint disease. Rheumatoid arthritis (RA) is a type of arthritis in which the body’s immune system mistakenly attacks the joints, causing chronic inflammation.
Early Signs of Arthritis in the Feet
There are more than 30 joints in the ankle and feet. Arthritis can affect one or multiple joints in the feet. Excess weight, hereditary tendencies, old injuries, and poor footwear are a few predisposing factors of arthritis.
Early Signs of Arthritis in the Fingers
The earliest signs of arthritis are pain, swelling and stiffness. If these symptoms are experienced in the fingers, it is likely because of rheumatoid arthritis. The signs and symptoms of arthritis in the fingers include popping sounds, joint deformity, warmth, mucus cysts and bone spurs.
Juvenile Rheumatoid Arthritis (JRA)
Juvenile rheumatoid arthritis (JRA) annually affects one child in every thousand. There are six types of JRA. Treatment of juvenile arthritis depends upon the type the child has and should focus on treating the symptoms that manifest.
What Is the Most Common Cause of Septic Arthritis in Kids?
Septic arthritis can be caused by bacterial, fungal or viral infections. Staphylococcus aureus, a type of bacteria, is the most common cause of septic arthritis in infants. Septic arthritis is a general term for any joint pain caused by infection of the joint.
Early Signs of Arthritis in the Knee
Arthritis refers to the redness and swelling of the joints. It usually develops slowly over 10 to 15 years, interfering with daily life activities. Knowing the early signs of arthritis can help you take appropriate treatment and incorporate modifications in your diet and lifestyle.
Early Signs of Arthritis in Shoulder
Early signs and symptoms of arthritis in the shoulder include pain in the shoulder joint that's worse when lifting heavy objects, pain that radiates down the arm and shoulder joint sounds like grinding, clicking, and crackling.
How Serious Is Rheumatoid Arthritis?
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that typically affects the joints and other body parts. If not diagnosed early and appropriately treated, RA can lead to permanent deformities, disabilities, and serious systemic complications.
Breastfeeding With Rheumatoid Arthritis
You can breastfeed your baby even if you have rheumatoid arthritis (RA). However, you must always consult your doctor before you start the process.
Do Steroids Help With Arthritis?
Arthritis is the inflammation of one or more joints in the body. The disease is one of the most common chronic health conditions in the United States. Steroids are a class of drugs that reduce inflammation and have a suppressing effect on the immune system.
Safest Rheumatoid Arthritis Drugs During Pregnancy
None of the drugs used in the treatment of rheumatoid arthritis (RA) is completely safe during pregnancy. You must discuss with your physician regarding the decision to use, modify, or stop any medications.
Osteoarthritis vs. Rheumatoid Arthritis
Osteoarthritis (OA) and rheumatoid arthritis (RA) are chronic joint disorders. RA is also an autoimmune disease. OA and RA symptoms and signs include joint pain, warmth, and tenderness. Over-the-counter pain relievers treat both diseases. There are several prescription medications that treat RA.
Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Non-radiographic spondyloarthritis (nr-axSpA) is an inflammatory arthritis that mainly affects the joints of the spine. Morning stiffness and back pain are the usual symptoms of nr-axSpA. Nonsteroidal anti-inflammatory drugs, exercise, and biologics are treatments for nr-axSpA.
What Are 5 Common Risk Factors to Rheumatoid Arthritis?
Rheumatoid arthritis (RA) is an autoimmune disorder (the body's immune system mistakenly attacks its own cells). Certain factors increase the risk of RA.
Early Signs and Symptoms of Arthritis in Thumb
The earliest sign and symptom of thumb arthritis is pain, swelling, and tenderness with activities that involve pinching action. The pain may be dull, achy, or sharp at the base of the thumb. The pain can occur when we grip, grasp, or pinch an object or use the thumb to apply force.
Early Signs of Arthritis in the Wrist
Wrist arthritis is inflammation (swelling) of one or more joints of the wrist. Wrist arthritis is long-lasting or permanent and eventually causes severe joint damage. The early signs of arthritis in the wrist include morning stiffness, redness, tenderness, pain, swelling, weakness, warmth and other symptoms.
Osteoarthritis and Treatment
Painful swelling of the joints due to wear and tear over many years is called osteoarthritis. Osteoarthritis may develop in any joint that includes the fingers, hips, and knees. There are many treatment options available to curb the complications of arthritis.
What Is the Main Cause of Osteoarthritis?
Osteoarthritis (OA) is a chronic degenerative disease of the joints affecting middle-aged and elderly people. It involves the breakdown of cartilage and associated inflammatory changes in the adjacent bone. It is a leading cause of chronic disability, affecting 30 million people in the United States alone.
Quackery of Arthritis
Arthritis patients are sometimes vulnerable to quackery (the business of promoting unproven remedies). These "quick fix" treatments are promoted as cure-alls, but they really have no right to such claims. Consumers should be wary of products that have marketing claims like "will cure," "ancient remedy," "has no side effects," and "revolutionary new scientific breakthrough." Read about arthritis remedies and tests that have no scientific proof of benefits.
Treatment & Diagnosis
- Rheumatoid Arthritis vs. Lupus: Differences and Similarities
- Steroids: for the Treatment of Arthritis
- What Is the Best Treatment for Arthritis?
- What Are the Four Stages of Osteoarthritis?
- What Is the Best Treatment for Osteoarthritis?
- What Is the Treatment for Septic Arthritis?
- Physical and Occupational Therapy for Arthritis
- Rheumatoid Arthritis (RA)
- Reactive Arthritis
- Psoriatic Arthritis
- Septic Arthritis
- Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
- Juvenile Idiopathic Arthritis
- Arthritis and Active Sports
- Arthritis Pain Relief Update
- Psoriatic Arthritis: Diagnosis and Treatment
- Osteoarthritis Specific References
- Arthritis Treatment Update
- Rheumatoid Arthritis FAQs
- Psoriatic Arthritis FAQs
- Osteoarthritis FAQs
- Why Does Pregnancy Affect the Course of Rheumatoid Arthritis (RA)?
- Are Corticosteroids Safe for Pregnant and Nursing Women with Rheumatoid Arthritis?
- What if I get COVID-19 with Rheumatoid Arthritis?
- Arthritis - Whether Weather Affects Arthritis
- Smoking: A New Risk - Rheumatoid Arthritis
- Arava Approved For Rheumatoid Arthritis
- 5 Surprising Facts About Rheumatoid Arthritis
- What Not to Eat When You Have Arthritis
- Are Women More Susceptible to Osteoarthritis?
- What Kind of Doctor Treats Ankylosing Spodylitis & Reactive Arthritis?
- What Is Meant by Seronegative Arthritis?
- What Is the Prognosis for Osteoarthritis?
- What Kind of Joint Injections Treat Osteoarthritis?
- What Are the Side Effects of Glucosamine?
- Are Hidradenitis and Rheumatoid Arthritis Related?
- What Is Sero Negative Arthritis?
- Will Rheumatoid Arthritis Nodules Go Away?
- What's the Rheumatoid Arthritis Prognosis?
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.